Silo Pharma Inc
SILO
NASDAQ
Biotechnology
$3.20
USD
-0.02 (-0.62%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.18M
Volume 28.0K
Revenue
$72,102
TTM
0.0%
YoY
Gross Margin
12%
TTM
-87.1%
YoY
Net Income
$-4.84M
TTM
-4.8%
YoY
Operating Cash Flow
$-3.84M
TTM
+17.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | -0.0 | -0.0 | -0.0 |
Selling, General & Administrative | 0.5 | 0.5 | 0.5 | 0.4 | 0.6 |
Other Operating Expenses | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 |
Total Operating Expenses | 1.1 | 1.3 | 1.1 | 0.8 | 1.6 |
Operating Income | -1.1 | -1.2 | -1.2 | -0.8 | -1.6 |
EBITDA | -1.1 | -1.2 | -1.1 | -0.8 | -1.6 |
Other Income / Expense | 0.0 | 0.0 | -0.0 | -0.1 | -0.1 |
Total Other Income / Expense | 0.1 | 0.0 | 0.0 | -0.1 | -0.1 |
Income Before Income Taxes | -1.0 | -1.2 | -1.1 | -0.9 | -1.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -1.0 | -1.2 | -1.1 | -0.9 | -1.6 |
Consolidated Net Income / Loss | -1.0 | -1.2 | -1.1 | -0.9 | -1.6 |
Net Income Attributable to Common Shareholders | -1.0 | -1.2 | -1.1 | -0.9 | -1.6 |
Basic EPS | -$0.23 | -$0.19 | -$0.12 | -$0.07 | -$0.12 |
Diluted EPS | -$0.23 | -$0.19 | -$0.12 | -$0.07 | -$0.12 |
Basic Shares Outstanding | 4.5M | 6.3M | 9.3M | 13.4M | 13.7M |
Diluted Shares Outstanding | 4.5M | 6.3M | 9.3M | 13.4M | 13.7M |